SEPs could be next in line for investor validity challenges as rumours grow of two big, new funds launching

As we approach the end of the year and consider the main trends of 2015 there’s no doubt that one of the biggest stories has been the IPR challenges to biotech and pharma patents filed by Erich Spangenberg and Kyle Bass. They’re not alone in seeing…

Get unlimited access to all IAM content